Stockscreener 앱 받기
6.67
14.80%
0.86
시간 외 거래:
6.79
0.12
+1.80%
전일 마감가:
$5.81
열려 있는:
$5.69
하루 거래량:
343.42K
Relative Volume:
1.75
시가총액:
$85.76M
수익:
$53.74M
순이익/손실:
$29.82M
주가수익비율:
2.9018
EPS:
2.2986
순현금흐름:
$-33.54M
1주 성능:
-5.26%
1개월 성능:
+56.21%
6개월 성능:
+260.54%
1년 성능:
+208.80%
1일 변동 폭
$5.51
$6.79
1주일 범위
$5.51
$7.80
52주 변동 폭
$1.345
$7.80
Q 32 Bio Inc Stock (QTTB) Company Profile
명칭
Q 32 Bio Inc
전화
781-999-0232
주소
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
6.67 | 74.71M | 53.74M | 29.82M | -33.54M | 2.2986 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | H.C. Wainwright | Buy |
| 2025-02-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | Raymond James | Strong Buy |
| 2024-09-11 | 개시 | Wells Fargo | Overweight |
| 2024-06-17 | 개시 | Guggenheim | Buy |
| 2024-05-21 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Piper Sandler | Overweight |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | 재확인 | BTIG Research | Neutral |
| 2022-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-02-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2020-12-14 | 재개 | H.C. Wainwright | Buy |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-24 | 개시 | Chardan Capital Markets | Buy |
| 2019-11-01 | 개시 | Oppenheimer | Perform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
모두보기
Q 32 Bio Inc 주식(QTTB)의 최신 뉴스
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Q32 Bio (NASDAQ:QTTB) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Best Momentum Stocks to Buy for March 13th - The Globe and Mail
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes - Markets Mojo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI) - The Globe and Mail
FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing - The Globe and Mail
What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings? - Defense World
Q1 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
H.C. Wainwright Maintains Buy on QTTB Q32 Bio Inc. March 2026 - Meyka
H.C. Wainwright reiterates Q32 Bio stock rating with $13 target - Investing.com India
Q32 Bio Reports Q4 2025 Financial Results, Highlights SIGNAL-AA Trial Progress and Strong Financial Runway into 2027 - Minichart
Q32 Bio Inc. (QTTB) Reports Q4 Earnings - AlphaStreet
Q32 Bio Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Q32 Bio 2025 Financial Results: Q4 Net Income $57.7M, Revenue $53.7MNews and Statistics - IndexBox
Q32 Bio (NASDAQ:QTTB) Releases Quarterly Earnings Results, Beats Expectations By $4.71 EPS - MarketBeat
Q32 Bio Inc. releases fourth quarter 2025 results and issues corporate update - Traders Union
Q32 Bio 10-K: $53.7M collaboration revenue drives $29.8M net income - TradingView
Q32 Bio: Q4 Earnings Snapshot - whas11.com
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Q32 Bio: Q4 Financial Overview - Bitget
Q32 Bio Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - Stocktwits
Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab - Defense World
QTTB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
QTTB PE Ratio & Valuation, Is QTTB Overvalued - Intellectia AI
FY2025 Earnings Estimate for Q32 Bio Issued By HC Wainwright - Defense World
Insider Selling: Q32 Bio (NASDAQ:QTTB) CFO Sells 3,995 Shares of Stock - MarketBeat
Insider Selling: Q32 Bio (NASDAQ:QTTB) Insider Sells 2,815 Shares of Stock - MarketBeat
Q32 Bio (QTTB) CSO auto-sells 2,815 shares to cover tax bill - Stock Titan
FY2025 Earnings Forecast for Q32 Bio Issued By HC Wainwright - MarketBeat
Insider Selling: Q32 Bio (NASDAQ:QTTB) CEO Sells $44,630.96 in Stock - MarketBeat
FY2029 Earnings Forecast for Q32 Bio Issued By HC Wainwright - Defense World
Analysts Offer Predictions for Q32 Bio FY2029 Earnings - MarketBeat
Q32 Bio (NASDAQ:QTTB) Now Covered by Analysts at HC Wainwright - Defense World
Q32 Bio (QTTB) Price Target Increased by 32.35% to 15.30 - Nasdaq
HC Wainwright & Co. Initiates Coverage of Q32 Bio (QTTB) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates Q32 Bio stock coverage with buy rating - Investing.com
QTTBQ32 BIO INC Latest Stock News & Market Updates - Stock Titan
Q32 Bio Inc. $QTTB Shares Sold by Monaco Asset Management SAM - MarketBeat
Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB) - Stock Titan
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight (2026-02-19) - Seeking Alpha
Point72, Steven A. Cohen disclose 9.9% stake in Q32 Bio (QTTB) - Stock Titan
Biotech Q32 Bio joins Oppenheimer health conference Feb. 25 webcast - Stock Titan
Q32 Bio Announces $10.5 Million Registered Direct Offering - The Globe and Mail
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Q32 Bio Inc has officially signed an agreement to issue and sell approximately 1.7 million shares of common stock. - Bitget
Q32 Bio (NASDAQ: QTTB) raises $10.5M to fund alopecia trials - Stock Titan
Q32 Bio Launches $10.5 Million Registered Direct Offering - marketscreener.com
Q 32 Bio Inc (QTTB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):